Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SYNTHETIC BLOOD POTENTIAL AS A DRUG DELIVERY SYSTEM

Executive Summary

SYNTHETIC BLOOD POTENTIAL AS A DRUG DELIVERY SYSTEM for petroleum-based drugs is noted in a May 7 press release by Synthetic Blood Corp. "The preliminary data indicates synthetic blood can transport many drugs, natrients, and enzyme systems without any significant loss of stability," the release states. "It represents an effective delivery system for the infusion of drugs." According to the release, synthetic blood is a sterile, water-based system consisting of two liquids of different densities which, when properly combined have the physical and chemical properties of human blood. It transports oxygen and when given in transfusion, can maintain or restore normal circulating volume and blood pressure. Metabolized in a similar fashion as natural blood, synthetic blood has the same physiological range and merges with the existing blood system, the company says. The product is envisioned as a potential replacement for human blood in a number of applications and as a direct replacement for blood plasma and volume extenders, the release indicated. The company, Synthetic Blood Corp., is a joint venture between Chicago-based Quixote Corp. and the venture capital arm of Allstate Insurance Company. Perfluorochemical (PFC) emulsions are currently the compounds farthest along in development as blood substitutes. The oxygen transport agent Fluosol-DA, a PFC manufactured by the Green Cross subsidiary Alpha Therapeutics, currently has an NDA as a red blood cell substitute pending. The company reports in the product's patent literature that synthetic blood has a wider range of properties than the oxygen transport agent Fluosol including an ability: to hold oxygen in reserve and release it in accordance with physiological tension; to add or disperse hemoglobin without loss of stability; and to transport nonpolar drug entities and enzyme systems without loss of stability. Synthetic blood does not contain Factor VIII, the clotting agent found in natural blood, but does not interfere with clotting mechanisms of the recipient's blood, the release maintains. Both product and process patents have been issued for the biological product and some limited animal testing has been performed. According to the company, synthetic blood is roughly 3-1/2 years away from clinical trials.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS008399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel